These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31629036)

  • 1. Lipid nanoparticles of Type-A CpG D35 suppress tumor growth by changing tumor immune-microenvironment and activate CD8 T cells in mice.
    Munakata L; Tanimoto Y; Osa A; Meng J; Haseda Y; Naito Y; Machiyama H; Kumanogoh A; Omata D; Maruyama K; Yoshioka Y; Okada Y; Koyama S; Suzuki R; Aoshi T
    J Control Release; 2019 Nov; 313():106-119. PubMed ID: 31629036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade.
    Li T; Hua C; Yue W; Wu J; Lv X; Wei Q; Zhu S; Zang G; Cui J; Liu YJ; Chen J
    Pharmacol Res; 2020 Nov; 161():105293. PubMed ID: 33176206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of Nonaggregating Poly-A Tailed Immunostimulatory A/D Type CpG Oligodeoxynucleotides Applicable for Clinical Use.
    Aoshi T; Haseda Y; Kobiyama K; Narita H; Sato H; Nankai H; Mochizuki S; Sakurai K; Katakai Y; Yasutomi Y; Kuroda E; Coban C; Ishii KJ
    J Immunol Res; 2015; 2015():316364. PubMed ID: 26380317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
    Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
    Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides.
    Yu C; An M; Li M; Liu H
    Mol Pharm; 2017 Aug; 14(8):2815-2823. PubMed ID: 28686452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-stranded phosphodiester cytosine-guanine oligodeoxynucleotide complexed with calcium phosphate as a potent vaccine adjuvant for activating cellular and Th1-type humoral immunities.
    Hanagata N; Li X; Chen MH; Li J; Hattori S
    Int J Nanomedicine; 2018; 13():43-62. PubMed ID: 29317815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists.
    Meng W; Yamazaki T; Nishida Y; Hanagata N
    BMC Biotechnol; 2011 Sep; 11():88. PubMed ID: 21943407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
    de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
    Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.
    Tada R; Muto S; Iwata T; Hidaka A; Kiyono H; Kunisawa J; Aramaki Y
    BMC Res Notes; 2017 Jan; 10(1):68. PubMed ID: 28126014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
    Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
    Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sharpening up tumor microenvironment to enhance the efficacy of immune checkpoint blockade on head and neck cancer using a CpG-oligodeoxynucleotide.
    Tseng JC; Yang JX; Liu YL; Su YW; Lee AY; Chen YW; Liu KJ; Luo Y; Hong YR; Chuang TH
    Cancer Immunol Immunother; 2022 May; 71(5):1115-1128. PubMed ID: 34581869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG-PEG Conjugates and their Immune Modulating Effects after Systemic Administration.
    Wu C; Xiang X; Yue Y; Li L; Li Y; Zhang C; Xu Y
    Pharm Res; 2018 Mar; 35(4):80. PubMed ID: 29500548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-quadruplex-based CpG oligodeoxynucleotide/DOTAP complex strongly stimulates immunity in CpG motif-specific and loop-length-dependent manners.
    Tu ATT; Hoshi K; Shobo M; Yamazaki T
    Nanomedicine; 2022 Feb; 40():102508. PubMed ID: 34906721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.
    Kato Y; Tabata K; Kimura T; Yachie-Kinoshita A; Ozawa Y; Yamada K; Ito J; Tachino S; Hori Y; Matsuki M; Matsuoka Y; Ghosh S; Kitano H; Nomoto K; Matsui J; Funahashi Y
    PLoS One; 2019; 14(2):e0212513. PubMed ID: 30811474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors.
    Liu C; Chu X; Yan M; Qi J; Liu H; Gao F; Gao R; Ma G; Ma Y
    Int J Pharm; 2018 Dec; 553(1-2):327-337. PubMed ID: 30393151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1.
    Yin P; Liu X; Mansfield AS; Harrington SM; Li Y; Yan Y; Dong H
    Oncotarget; 2016 Oct; 7(43):70223-70231. PubMed ID: 27602959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoparticles encapsulating hepatitis B virus cytosine-phosphate-guanosine induce therapeutic immunity against HBV infection.
    Lv S; Wang J; Dou S; Yang X; Ni X; Sun R; Tian Z; Wei H
    Hepatology; 2014 Feb; 59(2):385-94. PubMed ID: 23907803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphodiester backbone of the CpG motif within immunostimulatory oligodeoxynucleotides augments activation of Toll-like receptor 9.
    Pohar J; Lainšček D; Kunšek A; Cajnko MM; Jerala R; Benčina M
    Sci Rep; 2017 Nov; 7(1):14598. PubMed ID: 29097808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.